Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20969626 | 0.85 | TAAR1 (0.53) | TAAR1ADRA1AHTR2AHTR2CKDM4E | |
| SCHEMBL27668305 | 0.85 | MEP1B (0.47) | TAAR1ADRA1ACYP1A2HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL27730362 | 0.84 | MEP1B (0.46) | TAAR1ADRA1ACYP1A2HTR2AHTR2C | |
| SCHEMBL1253168 | 0.83 | AOC3 (0.64) | TAAR1ADRA1ACYP1A2AOC3HTR2A | |
| SCHEMBL10617782 | 0.82 | AOC3 (0.42) | TAAR1ADRA1ACYP1A2AOC3HTR2A | |
| Hydrochloric Acid SCHEMBL7366474 | 0.81 | AOC3 (0.62) | TAAR1ADRA1ACYP1A2AOC3HTR2A | |
| SCHEMBL24162329 | 0.81 | BCHE (0.47) | TAAR1 | |
| SCHEMBL8303296 | 0.80 | TAAR1 (0.52) | TAAR1ADRA1ACYP1A2AOC3HTR2A | |
| SCHEMBL9736373 | 0.79 | POLB (0.47) | TAAR1AOC3HTR2AKDM4EATM | |
| SCHEMBL5712533 | 0.79 | TAAR1 (0.50) | TAAR1ADRA1ACYP1A2AOC3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394789-B2 | (Dihydro)pyrrolo[2,1-α]isoquinolines | MSD OSS B.V. (NL) | 2013-03-12 | — | — | US | disclosed |
| US-8394789-B2 | (Dihydro)pyrrolo[2,1-α]isoquinolines | MSD OSS B.V. (NL) | 2013-03-12 | — | — | US | disclosed |
| US-8394789-B2 | (Dihydro)pyrrolo[2,1-α]isoquinolines | MSD OSS B.V. (NL) | 2013-03-12 | — | — | US | disclosed |
| EP-2252611-B1 | (DIHYDRO)PYRROLO[2,1-A]ISOQUINOLINES | ORGANON NV (NL) | 2011-10-05 | — | — | EP | disclosed |
| EP-2252611-B1 | (DIHYDRO)PYRROLO[2,1-A]ISOQUINOLINES | ORGANON NV (NL) | 2011-10-05 | — | — | EP | disclosed |
| US-20110039832-A1 | DIHYDRO)PYRROLO[2,1-A]ISOQUINOLINES | N.V. ORGANON (NL) | 2011-02-17 | — | — | US | disclosed |
| US-20110039832-A1 | DIHYDRO)PYRROLO[2,1-A]ISOQUINOLINES | N.V. ORGANON (NL) | 2011-02-17 | — | — | US | disclosed |
| US-20110039832-A1 | DIHYDRO)PYRROLO[2,1-A]ISOQUINOLINES | N.V. ORGANON (NL) | 2011-02-17 | — | — | US | disclosed |
| EP-2252611-A1 | (DIHYDRO)PYRROLO[2,1-A]ISOQUINOLINES | N.V. Organon (NL) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009098283-A1 | (DIHYDRO)PYRROLO[2,1-A]ISOQUINOLINES | N.V. ORGANON (NL) | 2009-08-13 | — | — | WO | disclosed |
| US-4255422-A | DIURETICS, TREATMENT OF CARDIOVASCULAR DISORDERS | SMITHKLINE CORPORATION (US) | 1981-03-10 | — | — | US | disclosed |
| US-4251525-A | FOR TREATING ANGINA PECTORIS | SMITHKLINE CORPORATION (US) | 1981-02-17 | — | — | US | disclosed |
| EP-0022330-A2 | Synergistic antihypertensive compositions | SMITHKLINE BECKMAN CORPORATION (US) | 1981-01-14 | — | — | EP | disclosed |
| US-4197297-A | 6-Halo-7,8-dihydroxy-1-(hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepines | SMITHKLINE CORPORATION (US) | 1980-04-08 | — | — | US | disclosed |
| US-4192872-A | ANTI -PARKINSONISM ACTIVITY | SMITHKLINE CORPORATION (US) | 1980-03-11 | — | — | US | disclosed |
| EP-0004794-A2 | Substituted benzazepines, processes for preparing them and pharmaceutical compositions containing them | SMITHKLINE BECKMAN CORPORATION (US) | 1979-10-17 | — | — | EP | disclosed |
| US-4171359-A | DOPAMINERGIC ACTIVITY | SMITHKLINE CORPORATION (US) | 1979-10-16 | — | — | US | disclosed |
| US-4160765-A | Method for 6-bromination of 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds | SMITHKLINE CORPORATION (US) | 1979-07-10 | — | — | US | disclosed |
| US-4111957-A | DOPAMINERGIC | SMITHKLINE CORPORATION (US) | 1978-09-05 | — | — | US | disclosed |
| US-4104379-A | DOPAMINERGIC ACTIVITY | SMITHKLINE CORPORATION (US) | 1978-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039832-A1 | DIHYDRO)PYRROLO[2,1-A]ISOQUINOLINES | PKD2, PKD1, CATSPER1 | TAAR1 3368/4885ADRA1A 490/4885CYP1A2 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.